N/A
Completed N=1,402
All-Case Surveillance of Prizbind®
Source: ClinicalTrials.gov NCT02946931 ↗Enrolled (actual)
1,402
Serious AEs
23.6%
Results posted
Dec 2021
Primary outcomePrimary: Number of Patients With Adverse Drug Reactions (ADRs) — 30 Participants
Summary
To evaluate safety and effectiveness of Prizbind® for Intravenous Solution 2.5 g under Japanese clinical condition.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Patients With Adverse Drug Reactions (ADRs) |
30 | — |
| SECONDARY Maximum Reversal of Anticoagulation as Measured by Activated Partial Thromboplastin Time (aPTT) |
100.0 | — |
| SECONDARY Number of Patients in Each Category of Maximum Reversal of Anticoagulation as Measured by Activated Partial Thromboplastin Time (aPTT) |
65; 16; 9; 13 | — |
Eligibility Criteria
Inclusion criteria
Patients who are prescribed with Prizbind® for Intravenous Solution 2.5 g by the discretion of investigators
Exclusion criteria
None
Data sourced from ClinicalTrials.gov (NCT02946931). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.